{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:51:50Z","timestamp":1774115510710,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,12,25]],"date-time":"2011-12-25T00:00:00Z","timestamp":1324771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s10096-011-1516-3","type":"journal-article","created":{"date-parts":[[2011,12,23]],"date-time":"2011-12-23T23:15:03Z","timestamp":1324682103000},"page":"1883-1887","source":"Crossref","is-referenced-by-count":23,"title":["Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis"],"prefix":"10.1007","volume":"31","author":[{"given":"A.","family":"Safdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,25]]},"reference":[{"key":"1516_CR1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/thx.2007.087999","volume":"63","author":"PA Jenkins","year":"2008","unstructured":"Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP (2008) Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 63:627\u2013634","journal-title":"Thorax"},{"key":"1516_CR2","unstructured":"Rodriguez G, Safdar A. Nontuberculous mycobacterial lung disease: a difficult-to-treat clinical syndrome of increasing significance in patients at a comprehensive cancer center (under review)"},{"key":"1516_CR3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/thorax.56.3.167","volume":"56","author":"Research Committee of the British Thoracic Society","year":"2001","unstructured":"Research Committee of the British Thoracic Society (2001) First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 56:167\u2013172","journal-title":"Thorax"},{"key":"1516_CR4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10096-008-0620-5","volume":"28","author":"DE Ghannam","year":"2009","unstructured":"Ghannam DE, Rodriguez GH, Raad II, Safdar A (2009) Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 28:253\u2013259","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1516_CR5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1309\/HN44-XQYM-JMAQ-2EDL","volume":"118","author":"XY Han","year":"2002","unstructured":"Han XY, Pham AS, Tarrand JJ, Sood PK, Luthra R (2002) Rapid and accurate identification of mycobacteria by sequencing hypervariable regions of the 16S ribosomal RNA gene. Am J Clin Pathol 118:796\u2013801","journal-title":"Am J Clin Pathol"},{"key":"1516_CR6","volume-title":"Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes; approved standard. M24-A","author":"National Committee for Clinical Laboratory Standards (NCCLS)","year":"2003","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS) (2003) Susceptibility testing of mycobacteria, Nocardia, and other aerobic actinomycetes; approved standard. M24-A. NCCLS, Wayne, PA"},{"key":"1516_CR7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1086\/317441","volume":"31","author":"GL Woods","year":"2000","unstructured":"Woods GL (2000) Susceptibility testing for mycobacteria. Clin Infect Dis 31:1209\u20131215","journal-title":"Clin Infect Dis"},{"issue":"2 Pt 2","key":"1516_CR8","first-page":"S1","volume":"156","author":"American Thoracic Society (ATS)","year":"1997","unstructured":"American Thoracic Society (ATS) (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 156(2 Pt 2):S1\u2013S25","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0002-9343(02)01313-X","volume":"113","author":"A Safdar","year":"2002","unstructured":"Safdar A, White DA, Stover D, Armstrong D, Murray HW (2002) Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med 113:756\u2013759","journal-title":"Am J Med"},{"key":"1516_CR10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-138-6-200303180-00030","volume":"138","author":"A Safdar","year":"2003","unstructured":"Safdar A, Armstrong D, Murray HW (2003) A novel defect in interferon-gamma secretion in patients with refractory nontuberculous pulmonary mycobacteriosis. Ann Intern Med 138:521","journal-title":"Ann Intern Med"},{"key":"1516_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2466-7-2","volume":"7","author":"KK Davis","year":"2007","unstructured":"Davis KK, Kao PN, Jacobs SS, Ruoss SJ (2007) Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 7:2","journal-title":"BMC Pulm Med"},{"key":"1516_CR12","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1164\/rccm.200805-686OC","volume":"178","author":"RD Kim","year":"2008","unstructured":"Kim RD, Greenberg DE, Ehrmantraut ME, Guide SV, Ding L, Shea Y et al (2008) Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 178:1066\u20131074","journal-title":"Am J Respir Crit Care Med"},{"key":"1516_CR13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1378\/chest.130.4.1234","volume":"130","author":"EA Waller","year":"2006","unstructured":"Waller EA, Roy A, Brumble L, Khoor A, Johnson MM, Garland JL (2006) The expanding spectrum of Mycobacterium avium complex-associated pulmonary disease. Chest 130:1234\u20131241","journal-title":"Chest"},{"issue":"Suppl 1","key":"1516_CR14","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1073\/pnas.1000087107","volume":"108","author":"L Dethlefsen","year":"2011","unstructured":"Dethlefsen L, Relman DA (2011) Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108(Suppl 1):4554\u20134561","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1516_CR15","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","volume":"38","author":"CA Peloquin","year":"2004","unstructured":"Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D (2004) Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 38:1538\u20131544","journal-title":"Clin Infect Dis"},{"key":"1516_CR16","unstructured":"Rodriquez GH, Rallapalli V, Safdar A. Aerosolized amphotericin B lipid complex for salvage therapy in cancer patients with difficult-to-treat pulmonary fungal disease (under review)"},{"key":"1516_CR17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bmt.1704552","volume":"34","author":"A Safdar","year":"2004","unstructured":"Safdar A, O\u2019Brien S, Kouri IF (2004) Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 34:467\u2013468","journal-title":"Bone Marrow Transplant"},{"key":"1516_CR18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s00134-010-1883-8","volume":"36","author":"A Safdar","year":"2010","unstructured":"Safdar A (2010) Feasibility of aerosolized colistin in the era of escalating drug-resistant Pseudomonas pneumonia: pressing need for validation clinical trials. Intensive Care Med 36:1110\u20131111","journal-title":"Intensive Care Med"},{"key":"1516_CR19","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1128\/AAC.40.11.2483","volume":"40","author":"N Rastogi","year":"1996","unstructured":"Rastogi N, Goh KS, Bryskier A, Devallois A (1996) Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 40:2483\u20132487","journal-title":"Antimicrob Agents Chemother"},{"key":"1516_CR20","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1128\/AAC.48.12.4562-4565.2004","volume":"48","author":"F Alcaide","year":"2004","unstructured":"Alcaide F, Calatayud L, Sant\u00edn M, Mart\u00edn R (2004) Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 48:4562\u20134565","journal-title":"Antimicrob Agents Chemother"},{"key":"1516_CR21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4065\/74.6.613","volume":"74","author":"S Alvarez-Elcoro","year":"1999","unstructured":"Alvarez-Elcoro S, Enzler MJ (1999) The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 74:613\u2013634","journal-title":"Mayo Clin Proc"},{"key":"1516_CR22","first-page":"301","volume":"11","author":"DE Griffith","year":"1996","unstructured":"Griffith DE, Wallace RJ Jr (1996) New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Semin Respir Infect 11:301\u2013310","journal-title":"Semin Respir Infect"},{"key":"1516_CR23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1378\/chest.07-0358","volume":"133","author":"J Glassroth","year":"2008","unstructured":"Glassroth J (2008) Pulmonary disease due to nontuberculous mycobacteria. Chest 133:243\u2013251","journal-title":"Chest"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-011-1516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-011-1516-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-011-1516-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T09:30:19Z","timestamp":1561109419000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-011-1516-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,25]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s10096-011-1516-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,25]]}}}